The other stem cells
Although embryonic stem cells dominate public discussion, a number of companies are building treatments, and businesses, around adult stem cells
BALTIMORE -- As Congress spent hours passionately debating the merits and ethics of embryonic stem cell research, nearly 50 Osiris Therapeutics Inc. employees here continued their quiet work on less controversial adult stem cells. (Full article: 1091 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $9.95 1 month archives pass
- $24.95 3 months archives pass
- $74.95 1 year archives pass
